Pfizer, Merck KGaA tout PhIII success for Bavencio; ImmunsanT gets a new investment from JDRF
→ Pfizer and Merck KGaA say their Phase III study of the checkpoint drug Bavencio combined with Inlyta came through for renal cell carcinoma patients, setting up some speedy applications for marketing approval. Researchers say it came through with PD-L1 expressing patients and the full population, demonstrating a significant PFS benefit compared to a control arm treated with Sutent. “JAVELIN Renal 101 is the first positive Phase III study combining an immune checkpoint blocker with a TKI, supporting the potential of BAVENCIO and INLYTA as a new cancer treatment approach for patients with advanced RCC,” said Chris Boshoff, Pfizer’s head of immuno-oncology, early development and translational oncology.
→ Cambridge, MA-based ImmusanT says it received an investment from JDRF T1D Fund, which backs new therapies for Type 1 diabetes. “This is an exciting time for ImmusanT as we expand the application of our ESIT platform beyond celiac disease to advance the development of a vaccine for type 1 diabetes, a disease for which there is significant unmet medical need,” said CEO Leslie Williams.
→ An Australian biotech touting an antibiotic therapy for coronary artery disease has bagged $5 million seed investment from an unnamed Chinese investor to get off the ground. Cadrock has just begun a clinical trial in Sydney for a therapy developed by noted gastroenterologist Thomas Borody, who theorizes that CAD is caused by a bacterial infection. Like the peptic ulcer bacterial infection treatment that brought him to fame, this experimental therapy is a triple antibiotic regime.